These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 28554411)

  • 21. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease.
    Delgado-Alvarado M; Gago B; Navalpotro-Gomez I; Jiménez-Urbieta H; Rodriguez-Oroz MC
    Mov Disord; 2016 Jun; 31(6):861-81. PubMed ID: 27193487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amyloid-β and τ biomarkers in Parkinson's disease-dementia.
    Buongiorno M; Compta Y; Martí MJ
    J Neurol Sci; 2011 Nov; 310(1-2):25-30. PubMed ID: 21764078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alpha-Synuclein Protofibrils in Cerebrospinal Fluid: A Potential Biomarker for Parkinson's Disease.
    von Euler Chelpin M; Söderberg L; Fälting J; Möller C; Giorgetti M; Constantinescu R; Blennow K; Zetterberg H; Höglund K
    J Parkinsons Dis; 2020; 10(4):1429-1442. PubMed ID: 33016895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma α-synuclein predicts cognitive decline in Parkinson's disease.
    Lin CH; Yang SY; Horng HE; Yang CC; Chieh JJ; Chen HH; Liu BH; Chiu MJ
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):818-824. PubMed ID: 28550072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of Alzheimer's-related plasma biomarkers with cognitive decline in Parkinson's disease.
    Mizutani Y; Ohdake R; Tatebe H; Higashi A; Shima S; Ueda A; Ito M; Tokuda T; Watanabe H
    J Neurol; 2023 Nov; 270(11):5461-5474. PubMed ID: 37480401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia].
    Toribio-Diaz ME; Carod-Artal FJ
    Rev Neurol; 2015 Jul; 61(1):14-24. PubMed ID: 26108904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease.
    Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM
    Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid biomarkers mirror rate of cognitive decline.
    Rolstad S; Berg AI; Bjerke M; Johansson B; Zetterberg H; Wallin A
    J Alzheimers Dis; 2013; 34(4):949-56. PubMed ID: 23313924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders.
    Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O
    Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson's disease.
    Compta Y; Valente T; Saura J; Segura B; Iranzo Á; Serradell M; Junqué C; Tolosa E; Valldeoriola F; Muñoz E; Santamaria J; Cámara A; Fernández M; Fortea J; Buongiorno M; Molinuevo JL; Bargalló N; Martí MJ
    J Neurol; 2015 Feb; 262(2):294-306. PubMed ID: 25380583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
    Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
    J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline.
    Jones JD; Rivas R; Luna K; Ryczek CA; Thomas KR
    Parkinsonism Relat Disord; 2023 Jan; 106():105221. PubMed ID: 36442366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.
    Bekris LM; Tsuang DW; Peskind ER; Yu CE; Montine TJ; Zhang J; Zabetian CP; Leverenz JB
    Mov Disord; 2015 Jun; 30(7):936-44. PubMed ID: 25808939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of visinin-like protein 1 concentrations in the cerebrospinal fluid of patients with mild cognitive impairment as a dynamic biomarker of Alzheimer's disease.
    Mroczko B; Groblewska M; Zboch M; Muszyński P; Zajkowska A; Borawska R; Szmitkowski M; Kornhuber J; Lewczuk P
    J Alzheimers Dis; 2015; 43(3):1031-7. PubMed ID: 25159667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of cerebrospinal fluid biomarkers to predict conversion to dementia in patients with mild cognitive impairment: a clinical cohort study.
    Tondelli M; Bedin R; Chiari A; Molinari MA; Bonifacio G; Lelli N; Trenti T; Nichelli P
    Clin Chem Lab Med; 2015 Feb; 53(3):453-60. PubMed ID: 25274948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Machine learning-based prediction of longitudinal cognitive decline in early Parkinson's disease using multimodal features.
    Almgren H; Camacho M; Hanganu A; Kibreab M; Camicioli R; Ismail Z; Forkert ND; Monchi O
    Sci Rep; 2023 Aug; 13(1):13193. PubMed ID: 37580407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.